ALTE1621, Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
Study ID: STU 042016-019
Summary
This is a Phase 2b randomized double-blind placebo controlled clinical trial to examine the effect of carvedilol on preventing cardiovascular morbidity/mortality associated with anthracycline exposure during childhood cancer treatment.